Targeting apoptosis to induce stable mixed hematopoietic chimerism and long-term allograft survival without myelosuppressive conditioning in mice

ERK-Dependent Bim Modulation Downstream of the 4-1BB-TRAF1 Signaling Axis Is a Critical Mediator of CD8 T Cell Survival In Vivo

(2014) L. Sabbagh et al.   JOURNAL OF IMMUNOLOGY

A Phase 1, Randomized Ascending Single-Dose Study of Antagonist Anti-Human CD40 ASKP1240 in Healthy Subjects

(2013) R. Goldwater et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Absence of donor CD40 protects renal allograft epithelium and preserves renal function

(2013) Anna Katharina Kraus et al.   TRANSPLANT INTERNATIONAL

Synergistic Bcl-2 inhibition by ABT-737 and cyclosporine A

(2012) Pietro E. Cippà et al.   APOPTOSIS

Resistance to ABT-737 in activated T lymphocytes: molecular mechanisms and reversibility by inhibition of the calcineurin–NFAT pathway

(2012) P E Cippà et al.   Cell Death & Disease

CD40 Blockade Combines with CTLA4Ig and Sirolimus to Produce Mixed Chimerism in an MHC-Defined Rhesus Macaque Transplant Model

(2011) A. Page et al.   AMERICAN JOURNAL OF TRANSPLANTATION

In vivo imaging of Treg cells providing immune privilege to the haematopoietic stem-cell niche

(2011) Joji Fujisaki et al.   NATURE

Induced Immune Tolerance for Kidney Transplantation

(2011) John D. Scandling et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immuno-intervention for the induction of transplantation tolerance through mixed chimerism

(2011) David H. Sachs et al.   SEMINARS IN IMMUNOLOGY

The BH3-mimetic ABT-737 inhibits allogeneic immune responses

(2011) Pietro E. Cippà et al.   TRANSPLANT INTERNATIONAL

Treg-Therapy Allows Mixed Chimerism and Transplantation Tolerance Without Cytoreductive Conditioning

(2010) N. Pilat et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Distinct Hematopoietic Stem Cell Subtypes Are Differentially Regulated by TGF-β1

(2010) Grant A. Challen et al.   Cell Stem Cell

Staying Alive: T Cell Costimulation, CD28, and Bcl-xL

(2010) T. H. Watts   JOURNAL OF IMMUNOLOGY

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

(2010) Wyndham H Wilson et al.   LANCET ONCOLOGY

Tolerance: an overview and perspectives

(2010) Herman Waldmann   Nature Reviews Nephrology

BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins represent another class of selective immune modulatory drugs

(2010) E. M. Carrington et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A CD8 T cell-intrinsic role for the calcineurin-NFAT pathway for tolerance induction in vivo

(2009) T. Fehr et al.   BLOOD

Critical roles of Bim in T cell activation and T cell–mediated autoimmune inflammation in mice

(2009) Maciej W. Ludwinski et al.   JOURNAL OF CLINICAL INVESTIGATION

Niche recycling through division-independent egress of hematopoietic stem cells

(2009) Deepta Bhattacharya et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The Bcl-2 Family Antagonist ABT-737 Significantly Inhibits Multiple Animal Models of Autoimmunity

(2009) P. D. Bardwell et al.   JOURNAL OF IMMUNOLOGY

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

(2008) C. Tse et al.   CANCER RESEARCH

Bcl-2 inhibitors: small molecules with a big impact on cancer therapy

(2008) M Vogler et al.   CELL DEATH AND DIFFERENTIATION

HLA-Mismatched Renal Transplantation without Maintenance Immunosuppression

(2008) Tatsuo Kawai et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical experience with mixed chimerism to induce transplantation tolerance

(2008) Thomas Fehr et al.   TRANSPLANT INTERNATIONAL